A pilot study of the effect of ezetimibe for postprandial hyperlipidemia

E-Zhong Xue, MBA, Ming-Hui Zhang, MMed, Chun-Li Liu, MMed*

Abstract

This study aimed to explore the feasible effect of ezetimibe for postprandial hyperlipidemia (PPHP).

Sixty participants were included in this study. Of these, 30 subjects in the intervention group received ezetimibe, while the remaining 30 participants in the control group did not undergo ezetimibe. All patients in intervention group were treated for a total of 2 weeks. Primary endpoints consisted of serum levels of total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG). Secondary endpoints included apoB-48, remnant lipoprotein cholesterol (RLP-C), blood glucose, insulin, hemoglobin A1c (HbA1c), and monocyte chemotactic protein (MCP). All outcomes were measured before and after 2-week treatment.

After 2-week treatment, participants in the intervention group did not show better outcomes in primary endpoints of Total-C, LDL-C, HDL-C, and TG; and secondary endpoints of apoB-48, RLP-C, blood glucose, insulin, HbA1c, and MCP, compared with subjects in the control group.

The results of this study showed that ezetimibe may be not efficacious for participants with PPHP after 2-week treatment.

Abbreviations: HbA1c = hemoglobin A1c, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, MCP = monocyte chemotactic protein, PPHP = postprandial hyperlipidemia, RLP-C = remnant lipoprotein cholesterol, TG = triglyceride, Total-C = total cholesterol.

Keywords: effect, ezetimibe, postprandial hyperlipidemia

1. Introduction

Previous studies have found that postprandial hyperlipidemia (PPHP) account for the development of atherosclerosis and coronary heart disease.[1-3] It does not only impair reflex regulation of the cardiovascular system, but also injury this system.[4,5] However, a substantial number of cases with coronary heart disease are still not prevented, and these residual risk factors remain are tricky issues.[6-8] Of these risk factors, the levels of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) are regarded to be the most important and risk ones.[9-11]

Ezetimibe is a novel cholesterol-absorption inhibitor that selectively inhibits cholesterol absorption.[12-15] It is often used to treat dyslipidemia.[15-18] A recent clinical study reported that it can be applied to reduce LDL-C by about 18%, and cardiovascular events about 2%, compared with statin.[19] The other study has reported that it can help to improve fasting and PPHP.[20] It works by suppression of intestinal chylomicron production in patients with PPHP.[21] However, limit data regarding the effect of ezetimibe monotherapy on PPHP was available. Thus, the aim of this retrospective study was tried to further investigate the potential effect of ezetimibe monotherapy in participants with PPHP.

2. Methods

2.1. Design

This retrospective study was conducted between April 2016 and November 2017 at the People’s Hospital of Yan’an. A total of 60 participants with PPHP were included. They were equally assigned to an intervention group and a control group. Subjects in the intervention group received ezetimibe for 2 weeks, while the participants in the control group did not receive ezetimibe during this period. The outcomes were measured before and after 2-week treatment.

This study was approved by the Medical Ethical Committee of the People’s Hospital of Yan’an. Written informed consent was obtained from all included subjects in this study.

2.2. Participant eligibility

All included subjects aged above 18 years old. In addition, all of them did not receive lipid-lowering medications. Participants were excluded if they had cancers, concomitant inflammatory conditions, or major surgery 6 months before the study. Additionally, they were also excluded if they had psychological diseases and insufficient personal information. Furthermore, cases were excluded if they did not have sufficient information, such as outcome and characteristics data.
2.3. Intervention

Participants in the intervention group underwent ezetimibe 10 mg/daily for a total of 2 weeks. The subjects in the control group did not administer ezetimibe during the treatment period. Participants continued their normal exercise and diet routines throughout the study period.

2.4. Outcome measurements

All the outcome data were measured by the laboratory tests. Primary endpoints included serum levels of total cholesterol (Total-C), TG, LDL-C, and HDL-C. Secondary endpoints consisted of apoB-48, remnant lipoprotein cholesterol (RLP-C), blood glucose, insulin, hemoglobin A1c (HbA1c), and monocyte chemotactic protein (MCP). All the outcomes were measured before and after 2-week treatment.

2.5. Statistical analysis

SPSS software (SPSS V.15.0, IBM Corp, Armonk, NY) was applied to analyze all the data. Continuous variables were analyzed by Mann–Whitney U test; categorical data were conducted by Fisher exact test. *P* < .05 was defined as the statistical significance.

3. Results

The characteristics of patient cases in both groups are showed in Table 1. There were no significant differences in all patient characteristics before the therapy between the intervention group and the control group.

Before the treatment, there were no significant differences regarding the primary endpoints of Total-C, LDL-C, HDL-C, and TG (Table 2); and secondary endpoints of apoB-48, RLP-C, blood glucose, insulin, HbA1c, and MCP (Table 3) between 2 groups.

After 2-week treatment, the comparison of primary endpoints (Total-C, *P* = .33; LDL-C, *P* = .67; HDL-C, *P* = .45; and TG, *P* = .29; Table 4), and secondary endpoints (apoB-48, *P* = .61; RLP-C, *P* = .44; blood glucose, *P* = .89; insulin, *P* = 30; HbA1C, *P* = .11; and MCP, *P* = .36; Table 5) still did not differ significantly between 2 groups.

4. Discussion

A previous study has explored the efficacy of ezetimibe on PPHP and lipoemia-induced endothelial dysfunction.[22] It included 20 participants with PPHP, and these subjects were divided into 2 groups equally.[22] Ten participants in the treatment group received ezetimibe, while the other 10 subjects in the control group did not receive ezetimibe. It found that PPHP is closely correlated with transient endothelial dysfunction.[22] Additionally, it found that ezetimibe enhances PPHP and its induced endothelial dysfunction.[22] However, the sample size of that study is too small, with 10 subjects each group only, to draw a firm conclusion.[22] Thus, it cannot provide strong evidence for the clinic as well as for further study.

The results of a previous study demonstrate that ezetimibe may be utilized to reduce levels of fasting and postprandial TG, PLP-C, and apoB-48 after fat loading test.[22] The other studies explored the effect of ezetimibe and also found that it could reduce levels of apoB-48 in male participants with mixed hyperlipemia.[23] Furthermore, another study also showed that

| Table 1 | Comparison of primary endpoints before the treatment. |
|--------|-----------------------------------------------------|
| Laboratory tests, mg/dL | Intervention group (n = 30) | Control group (n = 30) | P |
| Total-C | 218.5 (14.3) | 212.9 (13.7) | .12 |
| HDL-C | 62.2 (13.5) | 59.6 (12.4) | .44 |
| LDL-C | 131.7 (18.3) | 127.9 (19.7) | .43 |
| TG | 115.1 (36.6) | 113.7 (38.2) | .88 |

Data are present as mean ± standard deviation. HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TG = triglyceride, Total-C = total cholesterol.

| Table 2 | Comparison of secondary endpoints before the treatment. |
|--------|-----------------------------------------------------|
| Secondary endpoints | Intervention group (n = 30) | Control group (n = 30) | P |
| ApoB-48, μg/mL | 4.5 (2.1) | 4.4 (2.5) | .87 |
| RLP-C, mg/dL | 5.1 (1.8) | 5.0 (2.0) | .84 |
| Blood glucose, mg/dL | 92.3 (10.4) | 94.1 (11.3) | .52 |
| Insulin, μU/mL | 6.6 (2.2) | 6.3 (2.5) | .62 |
| HbA1C, % | 5.0 (0.2) | 5.0 (0.3) | 1.00 |
| MCP-1, pg/mL | 320.4 (42.8) | 299.5 (50.7) | .08 |

Data are present as mean ± standard deviation. ApoB-48 = apolipoprotein B, HbA1C = hemoglobin A1C, MCP = monocyte chemotactic protein, RLP-C = remnant lipoprotein cholesterol.
ezetimibe may be the decrease the TG and apoB-48 containing lipoproteins formation in the small intestine.\cite{24}

To our best knowledge, this is the study to investigate the feasible effect of ezetimibe alone for PPHP among Chinese population. The results of this study are inconsistent with the previous study.\cite{22} In the present study, the results did not show greater effect in both primary endpoints and secondary endpoints. It indicated that ezetimibe may not show promising effect for PPHP after 2-week treatment. However, it may work after longer intervention.

This study has 3 limitations. First, the sample size is still relatively small in this pilot study, although it included more subjects than the previous study.\cite{22} Second, the treatment duration of this study is quite short, with only 2 weeks, which may affect the results of this study. Third, this study was conducted at 1 hospital only. Thus, it may impact the generalization of the results to the other hospitals. Future studies should avoid these limitations.

5. Conclusion

The results of this study demonstrated that ezetimibe may be ineffective for subjects with PPHP after 2-week treatment. Further studies should extend the treatment period to further investigate its effect.

Author contributions

Conceptualization: Chun-Li Liu, E-Zhong Xue, Ming-Hui Zhang.

Data curation: Chun-Li Liu, E-Zhong Xue, Ming-Hui Zhang.

Formal analysis: E-Zhong Xue.

Investigation: Ming-Hui Zhang.

Methodology: E-Zhong Xue.

Project administration: Chun-Li Liu.

Resources: Chun-Li Liu, Ming-Hui Zhang.

Software: E-Zhong Xue.

Supervision: Chun-Li Liu.

Validation: E-Zhong Xue, Ming-Hui Zhang.

Visualization: E-Zhong Xue, Ming-Hui Zhang.

Writing – original draft: Chun-Li Liu, E-Zhong Xue, Ming-Hui Zhang.

Writing – review & editing: Chun-Li Liu, E-Zhong Xue, Ming-Hui Zhang.

References

[1] Herrmann W, Biermann J, Reuter W. Postprandial hyperlipemia, circadian rhythm and the stress test in lipid metabolism. Z Gesamte Inn Med 1986;41:489–93.

[2] Nakamura H, Ikewaki K, Nishiwaki M, et al. Postprandial hyperlipidemia and coronary artery disease. Ann N Y Acad Sci 1995;748:441–6.

[3] Teramoto T. Significance and management of hyperlipemia as a risk factor for the progression of arteriosclerosis. Nihon Naika Gakkai Zasshi 1997;86:439–43.

[4] Reimann M, Rüdiger H, Weiss N, et al. Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system. Atheroscler Suppl 2015;18:8–15.

[5] Ornon Y, Nebel L. Effects of hypervitaminosis D2 altered by pregnancy in rats: hyperlipidemia and fatty liver degeneration with restrained injuries to the cardiovascular system and other organs. Isr J Med Sci 1970;6:622–9.

[6] Nordoy A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipidemia. J Thromb Haemost 2003;1:690–7.

[7] Nakamura K, Miyoshi T, Yunoki K, et al. Postprandial hyperlipidemia as a potential residual risk factor. J Cardioil (Netherlands) 2016;67:135–9.

[8] Lupattelli G, Siepi D, De Vuono S, et al. Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia. Life Sci 2012;90:846–50.

[9] Kita T. Etiology and treatment of hyperlipemia. Nihon Naika Gakkai Zasshi 1997;86:439–43.

[10] Saito Y. Progress in the treatment of hyperlipemia. Nihon Naika Gakkai Zasshi 2004;93:1984–8.

[11] Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626–35.

[12] Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:455–62.

[13] Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003;23:1463–74.
[14] Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia. Ann Pharmacother 2003;37:839–48.
[15] Gupta EK, Ito MK. Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Heart Dis 2002;4:399–409.
[16] Yamaoka-Tojo M, Tojo T, Kosugi R, et al. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis 2009;8:41.
[17] Oikawa S, Yamashita S, Nakaya N, et al. Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. J Atheroscler Thromb (Japan) 2017;24:77–94.
[18] Katsuki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013;19:3107–14.
[19] Cannon CP, Blazing MA, Guigliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2187–97.
[20] Kurozumi A, Okada Y, Mori H, et al. Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes. Endocr J 2016;63:431–40.
[21] Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009;39:689–98.
[22] Yunoki K, Nakamura K, Miyoshi T, et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011;217:486–91.
[23] Tremblay AJ, Lamarche B, Hogue JC, et al. Effect of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res 2009;50:1463–71.
[24] Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb 2010;17:914–24.